Case number 1:19-cv-01497
Boehringer Ingelheim Pharmaceuticals Inc. v. Lupin Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Sep 11, 2019 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:18-cv-01689-CFC-SRF. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 18-1689-CFC ONLY. (nmf) |
| Sep 11, 2019 | 11 | SO ORDERED (12) Docket Text: SO ORDERED, re (83 in 1:18-cv-01689-CFC-SRF, 9 in 1:19-cv-01499-CFC, 8 in 1:19-cv-01498-CFC, 8 in 1:19-cv-01494-CFC, 7 in 1:19-cv-01492-CFC, 8 in 1:19-cv-01495-CFC, 8 in 1:19-cv-01501-CFC, 8 in 1:19-cv-01596-CFC, 9 in 1:19-cv-01500-CFC, 9 in 1:19-cv-01493-CFC, 8 in 1:19-cv-01594-CFC, 8 in 1:19-cv-01497-CFC, 7 in 1:19-cv-01496-CFC) STIPULATION Stipulation and [Proposed] Order for Consolidation. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 18-1689-CFC. Plaintiffs and Defendants shall follow the Scheduling Order entered in the Consolidated Action except for those deadlines outlined in this order. Signed by Judge Colm F. Connolly on 9/9/2019. Associated Cases: 1:18-cv-01689-CFC-SRF et al.(nmf) |
| Sep 4, 2019 | 9 | Answer to Complaint (15) Docket Text: ANSWER to [1] Complaint, Affirmative Defenses and, COUNTERCLAIM for Declaratory Judgment against Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. by Lupin Pharmaceuticals, Inc., Lupin Ltd..(Phillips, John) |
| Sep 4, 2019 | 10 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Lupin Ltd. for Lupin Ltd., Lupin Pharmaceuticals, Inc. filed by Lupin Ltd., Lupin Pharmaceuticals, Inc.. (Phillips, John) |
| Aug 30, 2019 | 8 | Stipulation (12) Docket Text: STIPULATION Stipulation and [Proposed] Order for Consolidation by Cipla Limited, Cipla USA, Inc., Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., MSN Laboratories Private Ltd., MSN Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Sun Pharmaceutical Industries, Inc., Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc.. (Phillips, John) |
| Aug 23, 2019 | 6 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation. Lupin Ltd. served on 8/14/2019, answer due 9/4/2019. (Egan, Brian) |
| Aug 23, 2019 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation. Lupin Pharmaceuticals, Inc. served on 8/14/2019, answer due 9/4/2019. (Egan, Brian) |
| Aug 14, 2019 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:19-cv-01492-CFC et al.(nmg) |
| Aug 12, 2019 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Lupin Ltd. on 8/12/2019; Lupin Pharmaceuticals, Inc. on 8/12/2019. Requesting party or attorney should pick up issued summons at the Help Desk, Room 4209, or call 302-573-6170 and ask the Clerk to mail the summons to them. (myr) |
| Aug 9, 2019 | 1 | Main Document (11) Docket Text: COMPLAINT filed against Lupin Ltd., Lupin Pharmaceuticals, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-2705738.) - filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc., Boehringer Ingelheim Corporation. (Attachments: # (1) Exhibit 1, # (2) Civil Cover Sheet)(myr) |
| Aug 9, 2019 | 1 | Exhibit 1 (48) |
| Aug 9, 2019 | 1 | Civil Cover Sheet (1) |
| Aug 9, 2019 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (myr) |
| Aug 9, 2019 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: May 23, 2019. Date of Expiration of Patent: April 3, 2034.Thirty Month Stay Deadline: 2/1/2022. (myr) |
| Aug 9, 2019 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,258,637 B2. (myr) |
| Aug 9, 2019 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent C. H. Boehringer Sohn AG & Co. KG for Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. filed by Boehringer Ingelheim Corporation, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals Inc. (myr) |
